Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W1YV
|
|||
| Former ID |
DIB008798
|
|||
| Drug Name |
PLX-5622
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 1 | [1] | |
| Company |
Plexxikon Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Granulocyte colony-stimulating factor receptor (G-CSF-R) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01282684) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.